Experimental Cancer Drug Access To Be Topic Of FDA Consensus Conference

FDA is planning a consensus conference to discuss issues surrounding single-patient INDs and expanded access programs for unapproved oncology agents, Oncologic Drug Products Division Medical Team Leader Grant Williams, MD, told FDA's Oncologic Drugs Advisory Committee June 7.